secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tyra Biosciences, Inc. (TYRA)
CIK:        0001863127
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-060235
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tyra Biosciences reports Q3 net loss $21.2M; cash $215.7M; advances TYRA-300 and TYRA-200 trials
--------------------------------------------------------------------------------

- Q3 2023 net loss $21.2M vs $12.5M YoY; R&D expenses $19.3M (prior $10.9M).
- Cash and equivalents $215.7M as of Sept 30, 2023; funds operations for at least two years.
- SURF301 Phase 1/2 for TYRA-300 (FGFR3 inhibitor) dose escalation ongoing; preclinical achondroplasia data positive.
- TYRA-200 Phase 1 in FGFR2-altered cholangiocarcinoma on track to dose first patient by YE 2023.
- FDA granted TYRA-300 Orphan Drug Designation for achondroplasia in July 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1863127/000095017023060235/0000950170-23-060235-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1863127/000095017023060235/tyra-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060235

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer